The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy of a gentleman undergoing active surveillance leading to reclassification of his disease as high risk prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909527 | PMC |
| http://dx.doi.org/10.1016/j.eucr.2016.04.012 | DOI Listing |
Publication Analysis
Top Keywords
prostate health
8
health phi
8
active surveillance
8
prostate cancer
8
elevated prostate
4
phi
4
phi biopsy
4
biopsy reclassification
4
reclassification active
4
prostate
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!